February 4, 2009 - The Medical Imaging & Technology Alliance (MITA) responds that the study by Jörg Hausleiter, M.D., in the Feb. 4 issue of the Journal of the American Medical Association (JAMA) correctly focuses on what providers need to know to ensure that computed tomography angiography (CTA) is utilized appropriately.

February 4, 2009 - According to a new market research report released this month by market research firm IMV Medical Information Division, the adoption of 64-slice CT equipment by cardiology practices throughout the U.S. has more than doubled over the past two years.

February 4, 2009 - On Thursday, Feb. 19 at 7:00 pm, The Halifax Health - Center for Cardiology, Daytona Beach, FL will present a live online panel discussion on an automated implantable cardiac defibrillator (ICD) surgical case.

February 3, 2009 - Bioheart Inc. has arranged with its Italian partner, Biomedica, for a complete grant-supported study of the Bioheart A&C Bio Science T-PLS Twin-Pulsatile Life Support System.

February 3, 2009 – Medtronic has completed enrollment in PROTECT, the company’s global study comparing its Endeavor drug-eluting stent (DES) to Johnson & Johnson’s Cypher DES.

February 2, 2009 - Boston Scientific Corp. today said it began patient enrollment in the PLATINUM clinical trial, which is designed to evaluate the company’s PROMUS Element Everolimus-Eluting Coronary Stent.

February 2, 2009 - Cardiac Dimensions Inc. today said it received the CE Mark approval for its CARILLON Mitral Contour System from KEMA Quality B.V., a European Union Notified Body from the Netherlands.

February 2, 2009 - CardiArc, Inc., along with Clinical Engineering Consultants Inc. (CEC) of Erlanger, KY, today said CEC will provide field service for the CardiArc HD-SPECT system.

CEC also brings technical consultation with CardiArc on the field service manual. In addition CEC will sell the CardiArc system in the Ohio River Valley area.

February 3, 2009 - The FDA has granted Pathway Medical Technologies Inc., 510(k) clearance to market its newest peripheral atherectomy catheter, the Jetstream G2, for use in the treatment of peripheral artery disease (PAD) in the lower limbs.

February 3, 2009 - Cerenis Therapeutics SA, a privately held pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, has in-licensed intellectual property supporting an investigational new treatment of aortic valve stenosis (AVS) based on HDL therapy.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now